Frequency Therapeutics to Participate in September Investor and Medical Conferences
08/30/2022 - 07:30 AM
LEXINGTON, Mass. --(BUSINESS WIRE)--
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that members of its management team will participate in investor and medical conferences later this month.
HC Wainwright 24th Annual Global Investment Conference : Company overview presentation by David Lucchino , CEO, Tuesday, September 13, 2022, 11 a.m. EST
American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNSF) 2022 Annual Meeting and OTO Experience : “Presentation on results of four single-dose trials of FX-322, showing improved speech perception” by Kevin Franck , Ph.D., SVP Marketing and New Product Planning, Tuesday, September 13, 2022 , 5 p.m. EST
Baird 2022 Global Healthcare Conference : Company overview presentation by David Lucchino , CEO, Wednesday, September 14, 2022 , 12:50 p.m. EST
A live webcast of the presentations from the HC Wainwright and Baird conferences can be accessed on the Investors & Media section of Frequency’s website . A replay will be posted following the event.
About Frequency Therapeutics
Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore human function – first in hearing loss and then in multiple sclerosis – by developing therapeutics that activate a person’s innate regenerative potential within the body through the activation of progenitor cells. Frequency’s hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for sensorineural hearing loss. Frequency is also advancing a pre-clinical program for remyelination in multiple sclerosis.
Headquartered in Lexington, Mass. , Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham , the Massachusetts Institute of Technology , and the Scripps Research Institute .
For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.
View source version on businesswire.com : https://www.businesswire.com/news/home/20220830005262/en/
Investor:
Carlo Tanzi , Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
617-914-0008
Media:
Frequency Therapeutics
Email: media@frequencytx.com
Source: Frequency Therapeutics, Inc.